Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532918 | 0.84 | ALDH1A1 (0.33) | ALDH1A1PTGS2HSD17B10CA12CA1 | |
| SCHEMBL10905874 | 0.69 | — | — | |
| SCHEMBL1369361 | 0.67 | — | — | |
| SCHEMBL3186057 | 0.67 | — | — | |
| SCHEMBL1369358 | 0.67 | — | — | |
| SCHEMBL20202177 | 0.67 | — | — | |
| SCHEMBL17958815 | 0.67 | CA1 (0.35) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL11624849 | 0.67 | CA12 (0.31) | CA12CA1CA2CA9 | |
| SCHEMBL445251 | 0.65 | CA12 (0.33) | ALDH1A1CA12CA1CA2CA9 | |
| Thiosemicarbazide SCHEMBL29028447 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087623-B2 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040235913-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | CUNY GREGORY D (US) | 2004-11-25 | — | — | US | disclosed |
| US-6699866-B2 | FOR THERAPY OF ADDICTION, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, HYPERTENSION, MIGRAINE, ALZHEIMER'S DISEASE, OBESITY, EMESIS, PSYCHOSIS, ANALGESIA, SCHIZOPHRENIA, PARKINSON'S DISEASE, RESTLESS LEG SYNDROME, SLEEPING DISORDERS | SEPRACOR INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002083863-A2 | THIAZOLE AND OTHER HETEROCYCLIC LIGANDS AND USE THEREOF | SEPRACOR, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235913-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | HTR5A, OPRL1, HTR2C | ALDH1A1 755/4885PTGS2 1101/4885HSD17B10 2239/4885 |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | HTR5A, OPRL1, HTR2C | ALDH1A1 755/4885PTGS2 1101/4885HSD17B10 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.